Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly

To the editor: Ruxolitinib is the first JAK inhibitor approved as therapy for high- and intermediate-risk myelofibrosis (MF). Two phase 3 trials have shown that ruxolitinib provides significant clinical benefit to patients with MF by reducing spleen size and ameliorating debilitating disease-